A Trial of Prednisolone in Combination With SPI-62 or Placebo in Subjects With Polymyalgia Rheumatica (PMR)
Key facts
- Who runs it
- Sparrow Pharmaceuticals
- Where
- Germany and Poland9 sites in 2 countriesChoose a country to see its sites
- Trial code
- NCT05436652
- EU 2024-517406-29-00
- EudraCT 2022-000299-20
- U1111-1312-2326
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 66 people enrolled
- Started
- 22 Jul 2022
- Ended
- 25 Apr 2025
- Type of study
- Interventional, 2 groups
- Treatments tested
- SPI-62
- SPI-62 matched placebo
- Prednisolone 10mg
- Additional prednisolone
- Additional prednisolone matched placebo
- Record updated
- 11 May 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (11)Hide the full registry criteria
Who can take part
- Written informed consent
- Diagnosis of PMR according to EULAR/ACR classification criteria
- Absence of PMR relapse based on symptoms and acute phase markers
- Daily oral prednisolone 10mg dose that will have been stable for at least 1-week at the Baseline visit and is expected to remain stable during the treatment period
Who cannot take part
- Use of medications for treatment of PMR within specified intervals prior to the Baseline Visit other than oral prednisolone
- Use of other medications likely to interfere with trial assessments
- Any current or prior medical condition, medical or surgical therapies, or clinical trial participation expected to interfere with the conduct of the trial or the evaluation of its results
- Any autoimmune disease (e.g., late-onset rheumatoid arthritis) other than PMR
- Any contraindication for prednisolone administration
- A diagnosis or any clinical features of giant cell arteritis
- History or diagnosis of endogenous hypercortisolism
Where is this trial?
It has sites in 2 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
This will be a single-blind, placebo-controlled phase 2 trial to compare prednisolone effects with and without SPI-62 in participants with PMR.
The 2 groups in the trial
- SPI-62Treatment being tested
Active drug / placebo by mouth each morning for up to 4 weeks + standard of care 10mg prednisolone. Each participant will receive both placebo and active drug but will be blinded to the sequence of active drug and placebo.
Treatment: SPI-62, SPI-62 matched placebo, and Prednisolone 10mg
- SPI-62 + additional prednisoloneTreatment being tested
Active drug / placebo by mouth each morning for up to 4 weeks + standard of care 10mg prednisolone + additional prednisolone or placebo. Each participant will receive both placebo and active drug but will be blinded to the sequence of active drug and placebo.
Treatment: SPI-62, SPI-62 matched placebo, Prednisolone 10mg, Additional prednisolone, and Additional prednisolone matched placebo
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Record updated
- 11 May 2025